EverSource Wealth Advisors’s Edgewise Therapeutics EWTX Stock Holding History

EverSource Wealth Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88K	Sell	71 -104	-59%	-$3.58K	﹤0.01%	3561
2026 Q1	$5.51K	Buy	175 +19	+12%	+$548	﹤0.01%	3224
2025 Q4	$3.87K	Buy	156 +14	+10%	+$281	﹤0.01%	3220
2025 Q3	$2.3K	Buy	142 +81	+133%	+$1.15K	﹤0.01%	3471
2025 Q2	$800	Buy	+61	New	+$880	﹤0.01%	3786
2025 Q1	–	Sell	-18	Closed	-$480	–	4073
2024 Q4	$480	Buy	+18	New	+$573	﹤0.01%	3212

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's EWTX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Edgewise Therapeutics (EWTX) stake by 59% in Q2 2026, selling an estimated $3.58K and leaving 71 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

EverSource Wealth Advisors first reported a position in EWTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.51K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

EverSource Wealth Advisors held 71 shares of Edgewise Therapeutics worth $2.88K as of Q2 2026.
EverSource Wealth Advisors sold 104 Edgewise Therapeutics shares in Q2 2026, an estimated $3.58K.
Edgewise Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3561 holding.
EverSource Wealth Advisors first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 6 quarters since.
EverSource Wealth Advisors's Edgewise Therapeutics position peaked at $5.51K in Q1 2026.
225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.